FAQ: Izotropic Corporation's IzoView Breast CT and Its Market Impact

What is Izotropic Corporation developing?

Izotropic Corporation is developing the IzoView Breast CT Imaging System, a breast imaging device designed to provide true 360-degree 3D imaging without compression.

How does the IzoView Breast CT pricing compare to competitors?

The IzoView Breast CT is priced at $500K, which is up to 67% lower than competing breast CT systems that can cost up to $1.5 million.

What imaging challenge does the IzoView system address?

It addresses the challenge of imaging dense breast tissue, where overlapping structures in compression-based imaging like mammography can mask cancers and delay diagnosis.

What is the significance of the 360-degree 3D imaging capability?

The true 360-degree 3D imaging without compression bridges the clinical gap between standard screening and MRI, offering 100x greater spatial resolution than MRI at significantly lower cost.

How does the platform approach benefit future expansion?

The platform approach enables 14 potential future indications across screening, diagnosis, monitoring, and treatment planning through software upgrades, creating scalable revenue expansion without hardware replacement.

What market problem does this technology solve?

It addresses the $8 billion annual burden in follow-up procedures, repeat imaging, and unnecessary interventions caused by inconclusive results from current screening technologies for women with dense breast tissue.

What are the stock symbols for Izotropic Corporation?

Izotropic Corporation trades under CSE: IZO and OTCQB: IZOZF.

Where can investors find the latest news and updates about Izotropic?

The latest news and updates are available in the company’s newsroom at ibn.fm/IZOZF.

What is the potential market size for this technology?

The IzoView Breast CT targets the $8.7 billion breast imaging market with potential for aggressive market displacement due to its competitive pricing and advanced imaging capabilities.